Technology

The present assays work through the detection of the host immune response to the earliest formation of cancer. Present theoretical analysis indicates that these assays can detect a tumor when the size is as small as 600 cells in mass. This size tumor is barely detectable by microscopic analysis.

Our autoantibody assays are unique in that they are formatted to detect the first changes in proteins shown when cancer is developing. The assays have been optimised to display the proper epitopes in the proper orientation to bind to autologous antibodies. These assays are grouped into panels that provide the maximum amount of information for the characterisation of a patient state.

These individual assays further provide the base for which analytical biochemistry and clinical results can be used to gain control of the relationship between tumour growth and immune response. By characterising the immune response at a given point in tumor progression, one can target therapeutics to a given phenotype.